Literature DB >> 21813414

Severe peripheral arterial disease during nilotinib therapy.

Philipp Le Coutre, Delphine Rea, Elisabetta Abruzzese, Hervé Dombret, Malgorzata M Trawinska, Susanne Herndlhofer, Bernd Dörken, Peter Valent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21813414     DOI： 10.1093/jnci/djr292

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  54 in total

1.  PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Authors:  A A Mian; A Rafiei; I Haberbosch; A Zeifman; I Titov; V Stroylov; A Metodieva; O Stroganov; F Novikov; B Brill; G Chilov; D Hoelzer; O G Ottmann; M Ruthardt
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

Review 2.  Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.

Authors:  Emanuel Raschi; Fabrizio De Ponti
Journal:  Intern Emerg Med       Date:  2011-12-13       Impact factor: 3.397

3.  Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.

Authors:  Peter Valent
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

4.  Next generation therapy in chronic myeloid leukemia.

Authors:  Pranab Kumar Bhattacharya; Upasana Bhattacharya; Rupak Bhattacharya; Ritwik Bhattacharya; Soumyak Bhattacharya; Rupsa Bhattacharya; Dalia Mukherjee; Oindrila Mukherjee; Debasis Mukherjee; Debasis Roy Barman; Soma Das; Anuradha Dey; Ranu Roy Biswas; Surajit Sarkar
Journal:  Indian J Hematol Blood Transfus       Date:  2012-04-08       Impact factor: 0.900

5.  Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib.

Authors:  K Mayer; G H Gielen; W Willinek; M C Müller; D Wolf
Journal:  Leukemia       Date:  2013-10-30       Impact factor: 11.528

Review 6.  Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

Authors:  Rongras Damrongwatanasuk; Michael G Fradley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-04

Review 7.  Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Lauren Caldemeyer; Michael Dugan; John Edwards; Luke Akard
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

8.  Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.

Authors:  Jorge E Cortes; H Jean Khoury; Hagop Kantarjian; Tim H Brümmendorf; Michael J Mauro; Ewa Matczak; Dmitri Pavlov; Jean M Aguiar; Kolette D Fly; Svetoslav Dimitrov; Eric Leip; Mark Shapiro; Jeff H Lipton; Jean-Bernard Durand; Carlo Gambacorti-Passerini
Journal:  Am J Hematol       Date:  2016-04-13       Impact factor: 10.047

Review 9.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

Review 10.  Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal:  Expert Rev Anticancer Ther       Date:  2013-12       Impact factor: 4.512
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.